주요우울증 환자에서 세로토닌 6(5-HT6) 수용체 C267T 다형성과 Citalopram 치료반응에 대한 연구

No Association between the 5-HT6 Receptor C267T Polymorphism and Response to Citalopram Treatment in Patient with Major Depressive Disorder

  • 한상우 (순천향대학교 의과대학 순천향대학병원 정신과학교실) ;
  • 임세원 (성균관대학교 의과대학 강북삼성병원 정신과학교실) ;
  • 오강섭 (성균관대학교 의과대학 강북삼성병원 정신과학교실) ;
  • 강이헌 (고려대학교 의과대학 신경정신과학교실) ;
  • 이민수 (고려대학교 의과대학 신경정신과학교실)
  • Hahn, Sang-Woo (Department of Psychiatry, Soonchunhyang University of College of Medicine) ;
  • Lim, Se-Won (Department of Psychiatry, Sungkunkwan University School of Medicine, Kangbuk Samsung Hospital) ;
  • Oh, Kang-Seob (Department of Psychiatry, Sungkunkwan University School of Medicine, Kangbuk Samsung Hospital) ;
  • Kang, Rhee-Hun (Department of Psychiatry, Korea University College of Medicine) ;
  • Lee, Min-Soo (Department of Psychiatry, Korea University College of Medicine)
  • 발행 : 2007.11.30

초록

The serotonin 6(5-HT6) receptor gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the C267T polymorphism in the 5-HT6 receptor gene and the treatment response to citalopram in a Korean population with major depressive disorder(MDD). Methods : Citalopram was administered for 8 weeks to the 90 patients who completed study. 21-item Hamilton depression rating scale(HAMD-21) was used as a outcome measure. Results : We found that the genotype, allele, and allele-carrier distributions did not differ significantly between MDD patients and normal controls. A main effect of an interaction of genotype with time on the decrease in the HAMD-21 score during the 8 weeks study period was not found. ANOVA revealed no significant effects of the C825T polymorphism on the decrease in the HAMD-21 score at each time period. Conclusions : These results suggest that the C267T polymorphism in the 5-HT6 receptor gene is not associated with the treatment response to citalopram.

키워드